DROSHA rs10719 T>C is associated with lymph node metastasis and clinical stage of gastric cancer patients.

ABSTRACT: It has been proved that polymorphisms in DROSHA are related to the risk and outcomes of several cancers. In our study, 97 patients with stage I-III gastric cancer treated with radical gastrectomy and adjuvant chemotherapy of oxaliplatin and fluoropyrimidines were analyzed. MassARRAY MALDI-TOF system was used to determine the genotypes. The 2-year DFS rate was 60.8% and the 3-year OS rate was 73.8%. In dominant model, we found that rs10719 TC+CC genotype carriers were less likely to develop lymph node metastasis (P=0.031). Compared with TC+CC genotype carriers, more patients with TT genotype were in stage III (P=0.021). The 3-year OS was significantly different for patients with or without lymph node metastasis (89.3% vs 63.3%, P=0.013) and for patients with stage I-III disease (100.0%, 88.6% and 55.8%, P=0.015). After the multi-variants' cox regression analysis, lymph node status (P=0.014, RR: 9.556, 95% CI: 1.586-57.590) was found to be an independent prognostic factor for these patients. These results suggested that DROSHA rs10719 T>C may be associated with lymph node metastasis and clinical stage of gastric cancer in a Chinese population.

SUBMITTER: Li J 

PROVIDER: S-EPMC6965246 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature